Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients (NCT06476132)
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients: A Randomized, Multicenter, Double Blind, Placebo-Controlled Trial (CTOT-47)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD. The primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.
Who can join: Review the eligibility criteria below.
Location: University of California, Los Angeles (Site #: 71123) — Los Angeles, California
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- University of California, Los Angeles (Site #: 71123) — Los Angeles, California
- Stanford University (Site #: 71141) — Palo Alto, California
- Johns Hopkins (Site #: 71119) — Baltimore, Maryland
- University of Minnesota (Site 71151) — Minneapolis, Minnesota
- Washington University (Site #: 71157) — St Louis, Missouri
- NYU Langone Health (Site #: 71177) — New York, New York
- Duke University (Site #: 71139) — Durham, North Carolina
- Cincinnati Children's Hospital Medical Center (Site #: 71017) — Cincinnati, Ohio
- Cleveland Clinic (Site #: 71101) — Cleveland, Ohio
- University of Pennsylvania (Site #: 71111) — Philadelphia, Pennsylvania
- Vanderbilt University Medical Center (Site #: 71174) — Nashville, Tennessee
- University Health Network/Toronto General Hospital (Site #: 71121) — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (310) 794-1999
Email: PLopez@mednet.ucla.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Transplant
- An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant — Cleveland, Ohio
- 10°C vs 4°C Lung Preservation RCT — Phoenix, Arizona
- Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction — Los Angeles, California
- GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation — Bethesda, Maryland
- A Study of Latin Dance for Post- Lung Transplant — Jacksonville, Florida
- Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension — Jacksonville, Florida
Explore by condition: All Lung Transplant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.